Related Experiment Video
Updated: Jun 20, 2026
Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
Current developments with peptide-based human tumor vaccines
Khashayarsha Khazaie1, Andreas Bonertz, Philipp Beckhove
1Division of Gastroenterology, Northwestern University Feinberg School of Medicine, Robert Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA. khazaie@northwestern.edu
Purpose Of Review:
Cancer immunology became scientifically credible only some 20 years ago with the demonstration of the existence of human tumor antigens. In this short time span, outcomes of cancer vaccine trials have raised hopes and also surfaced disappointments. This review focuses on the prospects of peptide-based vaccines in cancer immunotherapy.
Recent Findings:
Accurate descriptions of the natural immune responses to cancer allow for a more precise targeting of such tumors by boosting preexisting antitumor immune responses in patients. The development of synthetic long-peptide vaccines avoids many of the pitfalls of previous vaccination trials through the presence of multiple epitopes that may elicit memory antitumor immune responses. Furthermore, the combination of standard therapy with newly developed immunomodulating agents, such as antibodies blocking cytotoxic T lymphocyte-associated antigen-4 or programmed death receptor-1, and more efficient immune adjuvants has shown promising results.
Summary:
Immunotherapy is becoming an effective means of targeting human cancers, and the application of such approaches in combination with current standard schemes of treatment can lead to a significant benefit in survival and quality of life for cancer patients.
Insights
Peptide-based cancer vaccines show promise for immunotherapy by boosting natural antitumor responses. Combining these vaccines with immunomodulating agents and adjuvants improves patient survival and quality of life.
Area of Science:
- Oncology
- Immunology
Background:
- Cancer immunology gained credibility with the discovery of human tumor antigens.
- Cancer vaccine trials have yielded mixed results, highlighting the need for improved strategies.
Purpose of the Study:
- To review the prospects of peptide-based vaccines in cancer immunotherapy.
- To explore strategies for enhancing antitumor immune responses.
Main Methods:
- Review of existing literature on cancer immunology and vaccine development.
- Analysis of synthetic long-peptide vaccines and their potential benefits.
- Examination of combination therapies involving immunomodulating agents.
Main Results:
- Understanding natural anti-cancer immune responses enables precise tumor targeting.
- Synthetic long-peptide vaccines offer multiple epitopes to elicit memory immune responses, overcoming previous limitations.
- Combination therapies with checkpoint inhibitors (e.g., anti-CTLA-4, anti-PD-1) and advanced adjuvants show encouraging outcomes.
Conclusions:
- Cancer immunotherapy is an emerging effective strategy for treating human cancers.
- Combining immunotherapy with standard treatments significantly improves patient survival and quality of life.
More Related Videos
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy